Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clonazepam, ATC N03AE01 für die Zeit 01.08.2026 - 31.07.2028 (zzgl. Verlängerungsoption 1x12 Monate)

§ 130a (8) SGB V enables health insurers and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurers. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For the pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Clonazepam, ATC N03AE01, the DAK-Gesundheit intends to conclude pharmaceutical rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical rebate contracts. A rebate contract under the licensing model for the aforementioned substance comes into force for the first time on 01.08.2026 and ends on 31.07.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.